Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial.

Danson, S., Collinson, M., Plummer, E.R. et al. (17 more authors) (2025) Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial. In: Journal of Clinical Oncology. 2025 ASCO Annual Meeting II, 30 May - 03 Jun 2025, Chicago, USA. American Society of Clinical Oncology (ASCO)

Metadata

Item Type: Proceedings Paper
Authors/Creators:
  • Danson, S.
  • Collinson, M.
  • Plummer, E.R.
  • Ottensmeier, C.H.H.
  • Silva, S.
  • Hook, J.
  • Hapuarachi, B.S.
  • Wheater, M.
  • Payne, M.
  • Oladipo, O.
  • Waterston, A.M.
  • Velikova, G. ORCID logo https://orcid.org/0000-0003-1899-5942
  • Gallagher, F.A.
  • Meads, D.M.
  • Bell, S.E.
  • Greatorex, N.
  • Katona, E.
  • Bestall, J.
  • Daniels, S.
  • Corrie, P.G.
Dates:
  • Published (online): 4 June 2025
  • Published: 10 June 2025
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 27 Jun 2025 10:21
Last Modified: 27 Jun 2025 10:21
Status: Published
Publisher: American Society of Clinical Oncology (ASCO)
Identification Number: 10.1200/jco.2025.43.17_suppl.lba9508
Sustainable Development Goals:
  • Sustainable Development Goals: Goal 3: Good Health and Well-Being
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)